Drug Profile
Tezepelumab - Amgen/AstraZeneca
Alternative Names: AMG 157; MEDI-9929; Tezepelumab-ekko; TezspireLatest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; AstraZeneca
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma
- Phase III Eosinophilic oesophagitis; Rhinosinusitis
- Phase II Chronic obstructive pulmonary disease; Chronic urticaria
- Discontinued Atopic dermatitis
Most Recent Events
- 16 Apr 2024 Efficacy data from the phase II COURSE trial in Chronic obstructive pulmonary disease released by Amgen
- 16 Apr 2024 Amgen plans a phase III trial in Chronic obstructive pulmonary disease
- 23 Feb 2024 Efficacy data from a phase II INCEPTION trial in Chronic-urticaria presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)